JMP initiates NxStage at market outperform

NxStage Medical, Inc. coverage was initiated by JMP Securities analyst Robert C. Faulkner at a market outperform rating and a $13.50 price target. The positive stance is based on the strong demand drivers for the company's home hemodialysis product and the large market potential. If the company reaches JMP's current forecast assumptions, stock could triple in two years, JMP said. Shares of the Lawrence, Mass., medical device company were down 48 cents, or 5.01%, at $9.10 on volume of 45,542 shares versus the three-month running average of 74,767.6 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.